Thalidomide is more cost-effective than Velcade in MM but NICE lets doctors choose
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, following an appeal, upheld on June 17 its final draft guidance recommending Celgene's Thalidomide (thalidomide) as a more cost-effective first line option for some multiple myeloma patients, ahead of treatment with Janssen Cilag's Velcade (bortezomib). However, the second final appraisal determination, unlike the first, says that the final choice of treatment is down to the physician. Janssen Cilag welcomed the clarification.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.